Amylyx Pharmaceuticals (NASDAQ:AMLX) stockholders approved all proposals presented at the company’s 2026 Annual Meeting of Stockholders, including the election of two directors, the ratification of Deloitte & Touche LLP as the company’s auditor and an advisory vote on executive compensation.
The virtual meeting was chaired by Joshua Cohen, Amylyx’s co-chief executive officer. Cohen said the meeting was being conducted in accordance with the company’s bylaws and Delaware law. He also introduced members of the company’s board and executive team, including Justin Klee, director, co-chief executive officer and co-founder; Dr. George Milne; Paul Fonteyne; Daphne Quimi; Dr. Bernhardt Zeiher; Chief Financial Officer James Frates; and Chief Legal Officer and General Counsel Gina Mazzariello, who served as secretary of the meeting.
Quorum Established With Nearly 92% of Shares Represented
The company reported that stockholders of record as of April 10, 2026, were entitled to vote at the meeting. According to the report delivered during the meeting, proxies had been received for 102,074,387 of the 111,085,857 shares of common stock outstanding on the record date.
That represented approximately 91.89% of shares entitled to vote, which was sufficient to establish a quorum. The company also stated that a notice of internet availability of proxy materials had been mailed beginning April 24, 2026, giving stockholders access to the proxy card, proxy statement, notice of meeting and 2025 annual report, or the option to request printed materials.
Directors Elected Through 2029 Annual Meeting
Stockholders approved the election of George McLean Milne Jr., PhD, and Paul Fonteyne as Class II directors. They will serve on Amylyx’s board until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until any earlier resignation, removal or death.
Cohen said the company’s bylaws require advance notice from stockholders intending to nominate director candidates, and that no such notice had been received. As a result, the nominations for directors were closed before the vote. The board had recommended that stockholders vote in favor of each director nominee.
Auditor Ratification and Executive Compensation Approved
Stockholders also ratified the appointment of Deloitte & Touche LLP as Amylyx’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Cohen said stockholder ratification was not required under the company’s bylaws, but that the board submitted the matter as a matter of good corporate governance. He added that if stockholders had not approved the selection, the board and audit committee would have reconsidered the appointment.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of Amylyx’s named executive officers. The board had recommended voting in favor of the auditor ratification and executive compensation proposals.
No Stockholder Questions Submitted
During the question-and-answer portion of the meeting, Lindsey Allen, Amylyx’s vice president of investor relations and communications, reported that no questions had been submitted through the virtual meeting platform.
The polls opened at 9:06 a.m. Eastern Time and closed at 9:07 a.m. Eastern Time on Thursday, June 4, 2026. After the Inspector of Elections reported the results, Cohen declared that all proposals presented at the meeting had been approved or ratified by stockholders. He said the final voting results would be included in the meeting minutes and in Amylyx’s filings with the Securities and Exchange Commission.
With no other business before the meeting, Cohen adjourned the annual meeting.
About Amylyx Pharmaceuticals (NASDAQ:AMLX)
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
